Shattuck Labs Inc
STTK2.280USD
+0.050+2.24%
Handelsschluss 09/19, 16:00（ET）Kurse um 15 Minuten verzögert
109.22MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Shattuck Labs Inc Unternehmen
Shattuck Labs, Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Its lead product candidate, SL-172154, is designed to simultaneously inhibit the CD47/SIRPa macrophage checkpoint interaction and activate the CD40 costimulatory receptor to induce an antitumor immune response. It is conducting a Phase IA/B clinical trial in patients with acute myeloid leukemia (AML) and HR-MDS. It has completed the Phase IA dose-escalation portion of this clinical trial and are enrolling patients in the Phase IB expansion cohorts evaluating SL-172154 in combination with azacitidine in frontline HR-MDS or frontline TP53 mutant (TP53m) AML. It has developed the ARC platform to address the need for a single therapeutic that consolidates multiple immune functions.
Unternehmensinformationen
BörsenkürzelSTTK
Name des UnternehmensShattuck Labs Inc
IPO-datumOct 09, 2020
CEODr. Taylor Schreiber, M.D., Ph.D.
Anzahl der mitarbeiter44
WertpapierartOrdinary Share
GeschäftsjahresendeOct 09
Addresse500 W. 5Th Street
StadtAUSTIN
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl78701
Telefon15129004690
Websitehttps://www.shattucklabs.com/
BörsenkürzelSTTK
IPO-datumOct 09, 2020
CEODr. Taylor Schreiber, M.D., Ph.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Taylor Schreiber, M.D., Ph.D.
Dr. Taylor Schreiber, M.D., Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
96.61K
+36.07%
Dr. Stephen Stout, Ph.D.
Dr. Stephen Stout, Ph.D.
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
86.28K
+17.43%
Ms. Casi Deyoung
Ms. Casi Deyoung
Chief Business Officer
Chief Business Officer
81.47K
-8.97%
Dr. George S. Golumbeski, Ph.D.
Dr. George S. Golumbeski, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
54.61K
--
Dr. Neil W. Gibson ,Ph.D.
Dr. Neil W. Gibson ,Ph.D.
Independent Director
Independent Director
52.74K
--
Ms. Helen M. Boudreau
Ms. Helen M. Boudreau
Independent Director
Independent Director
--
--
Mr. Conor Richardson, CPA
Mr. Conor Richardson, CPA
Senior Director, Finance & Investor Relations
Senior Director, Finance & Investor Relations
--
--
Dr. Clay Siegall, Ph.D.
Dr. Clay Siegall, Ph.D.
Independent Director
Independent Director
--
--
Mr. Andrew R. Neill
Mr. Andrew R. Neill
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Abhinav A. Shukla, Ph.D.
Dr. Abhinav A. Shukla, Ph.D.
Chief Technical Officer
Chief Technical Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Taylor Schreiber, M.D., Ph.D.
Dr. Taylor Schreiber, M.D., Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
96.61K
+36.07%
Dr. Stephen Stout, Ph.D.
Dr. Stephen Stout, Ph.D.
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
86.28K
+17.43%
Ms. Casi Deyoung
Ms. Casi Deyoung
Chief Business Officer
Chief Business Officer
81.47K
-8.97%
Dr. George S. Golumbeski, Ph.D.
Dr. George S. Golumbeski, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
54.61K
--
Dr. Neil W. Gibson ,Ph.D.
Dr. Neil W. Gibson ,Ph.D.
Independent Director
Independent Director
52.74K
--
Ms. Helen M. Boudreau
Ms. Helen M. Boudreau
Independent Director
Independent Director
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, Sep 6
Aktualisiert: Sat, Sep 6
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Prosight Capital
13.86%
OrbiMed Advisors, LLC
13.16%
Redmile Group, LLC
11.56%
Adage Capital Management, L.P.
9.76%
Hornblower Capital Holdings, LLC
6.04%
Andere
45.62%
Aktionäre
Aktionäre
Anteil
Prosight Capital
13.86%
OrbiMed Advisors, LLC
13.16%
Redmile Group, LLC
11.56%
Adage Capital Management, L.P.
9.76%
Hornblower Capital Holdings, LLC
6.04%
Andere
45.62%
Aktionärstypen
Aktionäre
Anteil
Hedge Fund
28.47%
Investment Advisor/Hedge Fund
17.07%
Private Equity
13.16%
Corporation
12.56%
Investment Advisor
8.23%
Family Office
3.74%
Individual Investor
2.44%
Research Firm
1.52%
Andere
12.81%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
186
35.33M
73.76%
-6.35M
2025Q1
190
36.10M
75.45%
-5.76M
2024Q4
182
37.00M
77.49%
-7.77M
2024Q3
191
41.87M
87.75%
-1.86M
2024Q2
194
39.66M
83.35%
+16.66K
2024Q1
209
37.10M
79.60%
-1.39M
2023Q4
203
34.54M
71.04%
+5.75M
2023Q3
205
27.35M
64.28%
-7.93M
2023Q2
215
27.61M
64.91%
-8.42M
2023Q1
223
27.26M
64.10%
-8.88M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Prosight Capital
6.64M
13.86%
--
--
Mar 31, 2025
Redmile Group, LLC
5.54M
11.56%
--
--
Mar 31, 2025
Adage Capital Management, L.P.
4.67M
9.76%
--
--
Mar 31, 2025
Hornblower Capital Holdings, LLC
2.89M
6.04%
--
--
Apr 01, 2025
Houghton Capital Holdings, LLC
2.61M
5.45%
--
--
Apr 01, 2025
The Vanguard Group, Inc.
2.40M
5.01%
-7.92K
-0.33%
Mar 31, 2025
The Clark Estates Inc.
1.48M
3.08%
--
--
Mar 31, 2025
Pinnacle Associates Ltd.
1.30M
2.71%
-25.00K
-1.89%
Mar 31, 2025
683 Capital Management LLC
1.05M
2.19%
--
--
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
